Electrocardiographic characterization of the QTc interval in patients with advanced solid tumors: Pharmacokinetic-pharmacodynamic evaluation of sunitinib

Clinical Cancer Research

Volumn 15, Issue 22, 2009, Pages 7045-7052

  Bello, Carlo L ^a   Mulay, Marilyn ^b   Huang, Xin ^c   Patyna, Shem ^c   Dinolfo, Melissa ^b   Levine, Steven ^d   Van Vugt, Andrew ^b   Toh, Melvin ^c   Baum, Charles ^c   Rosen, Lee ^b  

^a PFIZER INC   (United States)

^b Premiere Oncology   (United States)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^d SAINT JOHN'S HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; GRANISETRON; LOPERAMIDE; MOXIFLOXACIN; SU 012662; SUNITINIB; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTHRALGIA; ARTICLE; BACKACHE; BRADYCARDIA; BRAIN DAMAGE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ELECTROCARDIOGRAPHY; FATIGUE; FEMALE; GAIT DISORDER; HAND PARESTHESIA; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; HYPOTENSION; LEUKOPENIA; LOADING DRUG DOSE; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; QT INTERVAL; RECOMMENDED DRUG DOSE; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; SKIN DISCOLORATION; SMALL INTESTINE OBSTRUCTION; SOLID TUMOR; SYNCOPE; TACHYCARDIA; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

ANTINEOPLASTIC AGENTS; ARRHYTHMIAS, CARDIAC; AZA COMPOUNDS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; GRANISETRON; HEART VENTRICLES; HUMANS; INDOLES; NEOPLASMS; PLACEBOS; PROTEIN-TYROSINE KINASES; PYRROLES; QUINOLINES; RISK; TIME FACTORS;

EID: 72549091339     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-1521     Document Type: Article

References (41)

1. International Registry for Drug-Induced Arrhythmias. Arizona Center for Education and Research on Therapeutics.
2. ICH E14: the clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. 2005.
3. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 inhibits KIT and platelet-derived growth factor receptor β in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003;2:471-478
4. Kim DW, Jo YS, Jung HS, et al. An orally administered-multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 2006;91:4070-4076
5. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327-337
6. Murray LJ, Abrams TJ, Long KR, et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 2003;20:757-766
7. O'Farrell AM, Foran JM, Fiedler W, et al. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res 2003;9:5465-5476 (Pubitemid 37499464)
8. Pfizer, Inc. Data on file.
9. Schueneman AJ, Himmelfarb E, Geng L, et al. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res 2003;63:4009-4016 (Pubitemid 36917920)
10. Adams VR, Leggas M. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors. Clin Ther 2007;29:1338-1353 (Pubitemid 47348120)
11. Bello C, Houk B, Sherman L, et al. J Clin Oncol 2005;23, (Abstract 3078).
12. Washington C, Eli M, Bello C, et al. The effect of ketoconazole (KETO), a potent CYP3A4 inhibitor, on SU011248 pharmacokinetics (PK) in Caucasian and Asian healthy subjects. Proc Am Assoc Cancer Res 2003;22:138s.
13. Rosen LS, Bello CL, Mulay M, Dinolfo M, Baum C. Aphase I study evaluating administration of oral SU11248 (sunitinib malate) using a loading and maintenance dose on a 2/1 schedule in patients (pts) with advanced solid tumors [abstract]. Proc Am Assoc Cancer Res 2006;47:684.
14. Trigo JM, Bellmunt J. [Current strategies in the treatment of renal-cell cancer: targeted therapies]. Med Clin (Barc) 2008;130:380-392
15. Baena-Cañada JM, Palomo González MJ, Arriola Arellano E, Benítez Rodríguez E. [Evolution of angiogenesis following anthracycline-based neoadjuvant chemotherapy in breast cancer] Spanish [abstract]. Med Clin (Barc) 2008;130:721-725
16. Cubo T, Padilla D, Villarejo P, López A. [Postoperative serum vascular endothelial growth factor can be a marker forcolorectal cancer recurrence] Spanish [abstract]. Med Clin (Barc) 2007;129:38-39
17. Mari Aparici C. [Introduction to the molecular imaging] Spanish [abstract]. Rev Esp Med Nucl 2006;25:394-409.
18. Strevel EL, Ing DJ, Siu LL. Molecularly targeted oncology therapeutics and prolongation of the QT interval. J Clin Oncol 2007;25:3362-3371
19. National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0 (CTCAE).
20. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-655
21. Morganroth J, Dimarco JP, Anzueto A, Niederman MS, Choudhri S. A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia. Chest 2005;128:3398-3406
22. Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R. Effects of three fluoroquinolones on QT interval in healthy adults after single doses. Clin Pharmacol Ther 2003;73:292-303.
23. Bello CL, Sherman L, Zhou J, et al. Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects. Anticancer Drugs 2006;17:353-358.
24. Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006;24:25-35. (Pubitemid 46630490)
25. Frederica LS. Dir Systolendaeur in Elektrokardiogram bei normalen Menchen und bei Herzkranken. Acta Med Scand 1920;53:469-486
26. Bazett HC. An analysis of the time-relations of electrocardiograms. Heart 1920;7:353-370
27. Sagie A, Larson MG, Goldberg RJ, Bengtson JR, Levy D. An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study). Am J Cardiol 1992;70:797-801.
28. Fiedler W, Serve H, Dohner H, et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 2005;105:986-993 (Pubitemid 40170865)
29. Bloomfield D, Kost J, Ghosh K, et al. The effect of moxifloxacin on QTc and implications for the design of thorough QT studies. Clin Pharmacol Ther 2008;84:475-480
30. Tsikouris JP, Peeters MJ, Cox CD, Meyerrose GE, Seifert CF. Effects of three fluoroquinolones on QT analysis after standard treatment courses. Ann Noninvasive Electrocardiol 2006;11:52-56
31. Liu Q, Madabushi R, Garrett C, Booth B. Experience in QT evaluation of oncology drug products since ICH E14 guidance [abstract]. J Clin Oncol 2008;25, (Abstract 2554).
32. Navari RM, Koeller JM. Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine3 receptor antagonists. Ann Pharmacother 2003;37:1276-1286 (Pubitemid 37040221)
33. Boike SC, Ilson B, Zariffa N, Jorkasky DK. Cardiovascular effects of i.v. granisetron at two administration rates and of ondansetron in healthy adults. Am J Health Syst Pharm 1997;54:1172-1176
34. Kovac AL. Benefits and risks of newer treatments for chemotherapy-induced and postoperative nausea and vomiting. Drug Saf 2003;26:227-259
35. Bhojani N, Jeldres C, Patard JJ, et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 2008;53:917-930
36. Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007;25:884-896
37. Motzer RJ, Hoosen S, Bello CL, Christensen JG. Sunitinib malate for the treatment of solid tumours: a review of current clinical data. Expert Opin Investig Drugs 2006;15:553-561
38. Pfizer Inc. SUTENT, summary of product characteristics. January 2008.
39. Sommargren CE, Drew BJ. Preventing torsades de pointes by careful cardiac monitoring in hospital settings. AACN Adv Crit Care 2007;18:285-293
40. Burstein HJ, Elias AD, Rugo HS, et al. Phase II study of sunitinib malate, an oral multi-targeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008;26:1810-1816
41. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:16-24. (Pubitemid 46630489)